LOVASTATIN (lovastatin) by PharmaIN is hydroxymethylglutaryl-coa reductase inhibitors [moa]. Approved for hmg-coa reductase inhibitor [epc]. First approved in 2006.
Drug data last refreshed 20h ago
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Worked on LOVASTATIN at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.